Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases

M. Bartneck, K.M. Scheyda, K.T. Warzecha, L.Y. Rizzo, K. Hittatiya, T. Luedde, Gerrit Storm, C. Trautwein, Twan Gerardus Gertudis Maria Lammers, F. Tacke

Research output: Contribution to journalArticleAcademicpeer-review

114 Citations (Scopus)
31 Downloads (Pure)


Liposomes are routinely used carrier materials for delivering drug molecules to pathological sites. Besides in tumors and inflammatory sites, liposomes also strongly accumulate in liver and spleen. The potential of using liposomes to treat acute and chronic liver disorders, however, has not yet been evaluated. We here explored the therapeutic potential of dexamethasone (Dex)-loaded liposomes for inflammatory liver diseases, using experimental models of acute and chronic liver injury in mice. Fluorescently labeled liposomes predominantly accumulated in hepatic phagocytes, but also in T cells. Importantly, Dex-loaded liposomes reduced T cells in blood and liver, more effectively than free Dex, and endorsed the anti-inflammatory polarization of hepatic macrophages. In experimental chronic liver damage, Dex-loaded liposomes significantly reduced liver injury and liver fibrosis. In immune-mediated acute hepatitis Dex-loaded liposomes, but not free Dex, significantly reduced disease severity. T cells, not macrophages, were significantly depleted by Dex liposomes in liver disease models in vivo, as further supported by mechanistic cell death in vitro studies. Our data indicate that Dex liposomes may be an interesting treatment option for liver diseases, in particular for immune-mediated hepatitis. The depletion of T cells might represent the major mechanism of action of Dex liposomes, rather than their macrophage-polarizing activities.
Original languageUndefined
Pages (from-to)367-382
Publication statusPublished - 2015


  • IR-99926
  • METIS-315199

Cite this